CAJ | 학술논문

目的：探讨靶向药物甲磺酸伊马替尼对高危胃肠间质瘤（GIST ）患者预后的影响。方法回顾性分析2008年1月～2013年5月手术治疗的97例原发高危GIST患者的临床病理及术后随访资料。结果97例患者中男性51例，女性46例，平均年龄57岁。肿瘤位于小肠（45．3％）、胃（42．3％）、结直肠（12．4％）。其中术后随访89例，中位随访时间33（6～96）个月，复发率43．8％（39例），死亡率20．2％（18例）。1，3和5年生存率分别为94．1％，83．2％和64．3％。术后43例服用甲磺酸伊马替尼，中位时间为28（9～74）个月。单因素和多因素预后分析显示，术后是否服用甲磺酸伊马替尼辅助治疗是影响预后的独立危险因素（P＜0．05）。结论术后给予靶向药物甲磺酸伊马替尼辅助治疗可明显改善原发高危GIST患者的预后。
목적：탐토파향약물갑광산이마체니대고위위장간질류（GIST ）환자예후적영향。방법회고성분석2008년1월～2013년5월수술치료적97례원발고위GIST환자적림상병리급술후수방자료。결과97례환자중남성51례，녀성46례，평균년령57세。종류위우소장（45．3％）、위（42．3％）、결직장（12．4％）。기중술후수방89례，중위수방시간33（6～96）개월，복발솔43．8％（39례），사망솔20．2％（18례）。1，3화5년생존솔분별위94．1％，83．2％화64．3％。술후43례복용갑광산이마체니，중위시간위28（9～74）개월。단인소화다인소예후분석현시，술후시부복용갑광산이마체니보조치료시영향예후적독립위험인소（P＜0．05）。결론술후급여파향약물갑광산이마체니보조치료가명현개선원발고위GIST환자적예후。
Objective To explore the influence of targeted drug imatinib adjuvant treatment on high‐risk patients with gastrointesti‐nal stromal tumors .Methods Clinical data of 97 patients with primary high‐risk GIST undergoing surgical treatment from January 2008 to May 2013 were reviewed retrospectively .Results Ninety‐seven patients were comprised of 51 males and 46 females with average age of 57 years .Of 97 tumors ,45 .3% located in the small intestine ,42 .3% in the stomach ,and 12 .4% in the colorectal . 89 patients were followed up with a median time of 33 months ,ranging from 6 to 96 months .The recurrence rate was 43 .8% (39/89) and the mortality rate was 20 .2% (18/89) .The 1 ,3 and 5year survival rates were 94 .1% ,83 .2% and 64 .3% ,respectively .43 patients received targeted therapy of imatinib after surgery and the median duration was 28 (9‐74)months .Univariate and multivariate analysis showed that imatinib treatment after surgery was an independent prognostic factor (P<0 .05) .Conclusion Adjuvant targeted therapy of imatinib after surgery can improve the survival of primary high‐risk GIST patients .